Escitalopram

ApprovedUNKNOWN

0 views this week 0 watching💤 Quiet

Interest: 36/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Obsessive Compulsive Disorder

Conditions

Obsessive Compulsive Disorder

Trial Timeline

Jan 1, 2007 → Dec 1, 2010

NCT ID

NCT00708240

About Escitalopram

Escitalopram is a approved stage product being developed by Lundbeck for Obsessive Compulsive Disorder. The current trial status is unknown. This product is registered under clinical trial identifier NCT00708240. Target conditions include Obsessive Compulsive Disorder.

What happened to similar drugs?

4 of 9 similar drugs in Obsessive Compulsive Disorder were approved

Approved (4) Terminated (1) Active (4)

✅DuloxetineEli LillyApproved

🔄Fluvoxamine maleate + PlaceboAbbViePhase 3

🔄quetiapine fumarate + SSRI/ClomipramineAstraZenecaPhase 3

✅Clomipramine (fluoxetine plus clomipramine) + Quetiapine (fluoxetine plus quetiapine) + Placebo (fluoxetine plus placebo)NovartisApproved

✅pregabalin + PlaceboPfizerApproved

✅Escitalopram + Placebo oral tabletLundbeckApproved

🔄Troriluzole + PlaceboBiohavenPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (14)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00902564	Approved	Completed	Mar 1, 2009	Mar 1, 2010	Generalized Anxiety Disorder
NCT00902226	Approved	Completed	Mar 1, 2009	Mar 1, 2010	Social Anxiety Disorder
NCT00935246	Pre-clinical	UNKNOWN	Dec 1, 2008	Dec 1, 2016	Depression
NCT00442481	Approved	UNKNOWN	Feb 1, 2007	—	Major Depressive Disorder
NCT00708240	Approved	UNKNOWN	Jan 1, 2007	Dec 1, 2010	Obsessive Compulsive Disorder
NCT00397059	Approved	Completed	Dec 1, 2006	Oct 1, 2007	Healthy
NCT00456937	Approved	Completed	Jul 1, 2006	Sep 1, 2008	Schizophrenia
NCT00464191	Approved	Terminated	Apr 1, 2006	Mar 1, 2009	Bipolar Disorder
NCT00243477	Approved	Completed	Jan 1, 2006	Feb 1, 2012	Coronary Artery Disease
NCT00232700	Pre-clinical	Completed	Sep 1, 2005	Dec 1, 2008	Major Depressive Disorder
NCT00162968	Approved	Completed	Dec 1, 2004	Apr 1, 2007	Pain
NCT00229333	Approved	UNKNOWN	Dec 1, 2004	—	Depressive Syndrome
NCT00140257	Approved	UNKNOWN	Nov 1, 2004	—	Depression
NCT00148447	Phase 3	Completed	Nov 1, 2004	Sep 1, 2005	Schizophrenia

Competing Products

17 competing products in Obsessive Compulsive Disorder

See all competitors

Product	Company	Stage	Hype Score
Duloxetine	Eli Lilly	Approved	43
Fluvoxamine maleate + Placebo	AbbVie	Phase 3	40
quetiapine fumarate + SSRI/Clomipramine	AstraZeneca	Phase 3	40
Quetiapine	AstraZeneca	Phase 2	35
Clomipramine (fluoxetine plus clomipramine) + Quetiapine (fluoxetine plus quetiapine) + Placebo (fluoxetine plus placebo)	Novartis	Approved	43
Bitopertin + Placebo + SSRI	Roche	Phase 2	35
sertraline	Pfizer	Pre-clinical	26
pregabalin + Placebo	Pfizer	Approved	43
Sertraline + Levetiracetam + Placebo	UCB	Phase 2/3	30
Escitalopram + Placebo oral tablet	Lundbeck	Approved	44
Valbenazine + Placebo	Neurocrine Biosciences	Phase 2	39
RG1068 (Synthetic Human Secretin)	Repligen	Phase 2	32
Troriluzole + Placebo	Biohaven	Phase 3	34
Troriluzole + Placebo	Biohaven	Phase 3	34
Troriluzole + Placebo	Biohaven	Phase 2/3	32
Troriluzole (BHV-4157)	Biohaven	Phase 3	26
Nitrous Oxide + Nitrogen	Brain Biotech	Phase 2	32